Drug Profile
Research programme: antibacterial nanotherapeutics - Techulon
Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Techulon
- Class Antibacterials; Peptide nucleic acids
- Mechanism of Action Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pseudomonal infections
- Research Acinetobacter infections; Gram-negative infections
- No development reported Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in USA (Parenteral)
- 24 Sep 2020 Early research in Acinetobacter infections in USA (Parenteral) (Techulon website, September 2020)
- 24 Sep 2020 Early research in Gram-negative infections in USA (Parenteral) (Techulon website, September 2020)